Related Articles
Effectiveness of the bevacizumab‑irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second‑line treatments without this regimen
Valganciclovir and bevacizumab for recurrent glioblastoma: A single-institution experience
Multicenter phase II study of fractionated bimonthly oxaliplatin with leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer, pre-treated with chemotherapy
Modified FLOX as first-line chemotherapy for metastatic colorectal cancer patients in the public health system in Brazil: Effectiveness and cost-utility analysis
Cost‑effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma